Previous 10 | Next 10 |
2023-11-28 23:26:48 ET Summary Abrams' 13F portfolio value decreased from $3.48B to $3.03B this quarter, with the number of holdings decreasing from 16 to 14. The top three stakes make up approximately 49% of the portfolio, while the top five holdings account for around 67%. T...
2023-11-28 12:45:05 ET Teva Pharmaceutical Industries Limited (TEVA) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 08:20 AM ET Company Participants Richard Francis - President and Chief Executive Officer Eric Hughes - Executive Vice President, Globa...
2023-11-27 11:35:47 ET More on Teva Pharmaceutical Teva: Deeply Undervalued FCF Machine Teva Pharmaceutical Industries Limited (TEVA) Q3 2023 Earnings Call Transcript Teva Pharmaceutical Industries Limited 2023 Q3 - Results - Earnings Call Presentation Teva g...
2023-11-22 06:42:30 ET Summary Under Armour has struggled for the better part of a year. However, it shows signs of bottoming, due to a better technical and fundamental picture. Fundamentals in particular make the stock a compelling buy. The company is very cheap on a PEG ...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of th...
2023-11-20 16:21:22 ET Summary Teva is an Israeli pharmaceutical company and the largest global generic manufacturer which suffered numerous challenges in recent years. The new management has a clear vision of how to deliver value to shareholders with the help of the company's str...
2023-11-17 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-17 09:26:34 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Q3 2023 Earnings Call Transcript Teva Pharmaceutical Industries Limited 2023 Q3 - Results - Earnings Call Presentation Teva: Focus On Innovation And Growth Means The Time...
Forteo® (teriparatide injection) is indicated to treat osteoporosis among certain women and men. This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering. The approval and subsequent launch will enhance access t...
2023-11-13 13:58:11 ET Summary Corcept Therapeutics' strategic shift to relacorilant from Korlym addresses efficacy and safety, amidst Teva's patent dispute. Financially robust with 21.5% YOY revenue growth; however, increasing R&D costs and potential generic competition are c...
News, Short Squeeze, Breakout and More Instantly...
Teva Pharmaceutical Industries Limited American Depositary Shares Company Name:
TEVA Stock Symbol:
NYSE Market:
Teva Pharmaceutical Industries Limited American Depositary Shares Website:
SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emerg...
2024-07-10 08:00:08 ET Ashwani Verma from UBS issued a price target of $24.00 for TEVA on 2024-07-10 07:20:00. The adjusted price target was set to $24.00. At the time of the announcement, TEVA was trading at $15.81. The overall price target consensus is at $15.00 with h...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8...